News on noninvasive prenatal testing, carrier screening, and preimplantation genetic screening.
DiaSorin said its Liaison Testosterone xt test enables the detection of fertility disorders, such as hypogonadism in men and hyperandrogenism in women.
As reported in April, revenues for the fiscal year ended March 31 totaled £16.6 million ($21.4 million), up from £8.9 million in FY2019.
The coverage comes after the women's health diagnostics firm went public last month, seeking up to $100 million in the offering.
First Genetics will market its F-Genetics NGS System and IVD assays to Russian laboratories for reproductive health testing and cancer diagnostics.
Natera sued Progenity in June but the firm said its Innatal cell-free DNA noninvasive prenatal test does not infringe any of Natera's six patents.
